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IN EPITHELIA and some nonepithelial tissues, ClC-2 and CFTR Cl Ϫ channels are often present together (3, 5, 8, 14, 18, 23, 34 -36, 46, 48) . Commonly, Cl Ϫ transport across epithelial tissues is measured by short-circuit current (I sc ), and this measurement does not distinguish between ClC-2-and CFTRmediated I sc . Although it is possible to differentiate between these two channels at the single-channel level, as in A6 cells (3) , single-channel measurements require specialized electrophysiological equipment and expertise and are often beyond the capabilities of many laboratories. ClC-2 and CFTR Cl Ϫ channels can also be distinguished by their biophysical properties in whole cell patch clamp. However, when both channels are present in a single cell type, they can only be distinguished if one or the other of the channels is selectively activated or inhibited, but not if both are activated or inhibited similarly. Alternately, ClC-2 and CFTR could be knocked out or knocked down by appropriate procedures for study of these two Cl Ϫ channels individually. However, this is a major undertaking, but a powerful tool. Therefore, the present study was designed to examine whether pharmacological agents could be used to functionally distinguish between ClC-2 and CFTR Cl Ϫ channel currents in cells, particularly in I sc measurements of epithelial cultures. In the present context, interpretation of any effects of pharmacological agents depends on whether they affect ClC-2, CFTR, or both channels. Therefore, it was important to test such agents on each target channel separately before drawing conclusions. Inhibitors that differentially inhibit ClC-2 or CFTR would be useful in such studies. CFTR inhibitor 172 (CFTR inh 172), originally identified as a CFTR inhibitor that did not inhibit Ca 2ϩ -activated Cl Ϫ channels, volume-activated Cl Ϫ channels, an ATP-activated K ϩ channel, or several other transporters (25) , has been extensively used to suggest exclusive involvement of CFTR in Cl Ϫ secretion in many different cell types, including T84 cells (2, 4, 33, 45) . However, effects of CFTR inh 172 on ClC-2 Cl Ϫ channel currents have not been determined. Other CFTR inhibitors, N-(4-methylphenylsulfonyl)-N=-(4-trifluoromethylphenyl)urea (DASU-02) and DASU-01, have been described (31, 39, 49) , but their effects on ClC-2 have also not been studied extensively. Whether these inhibitors could differentially inhibit CFTR, and not ClC-2, is unknown. Recently, methadone was identified to be an inhibitor of recombinant human ClC-2 (hClC-2), but not recombinant human CFTR (hCFTR), with half-maximal inhibition (IC 50 ) at 100 nM (7) , suggesting that it can be used to differentially inhibit ClC-2, but not CFTR. Interestingly, recently, a peptide toxin inhibitor, GaTx2, was identified and shown to differentiate between ClC-2 and CFTR (47) . It potently, but partially, inhibited ClC-2 (IC 50 ϳ20 pM) by ϳ80% and had no effect on CFTR, even at 60 nM. It also did not inhibit ClC-1, ClC-3, ClC-4, Ca 2ϩ -activated Cl Ϫ , or GABA C Cl Ϫ channels or major voltage-activated K ϩ channels. In the present study, effects of CFTR inh 172 and DASU-02, two CFTR inhibitors (25, 31) , and methadone (7) were examined by whole cell patch clamp on Cl Ϫ currents in recombinant human ClC-2/human embryonic kidney 293 (ClC-2/HEK293) cells stably transformed with Epstein-Barr nuclear antigen 1 (hClC-2/293EBNA) and hCFTR/HEK293 cells, by I sc in T84 cells, and by whole cell patch clamp in two additional cell models: T84 cells in which ClC-2 or CFTR was knocked down using siRNA (T84 ClC-2 KD and T84 CFTR KD cells, respectively). It should be noted that T84 cells that contain a large amount of mRNA for ClC-2 were used to clone hClC-2 (6) . Cl Ϫ currents were activated with lubiprostone and forskolin-IBMX in patch-clamp studies and with lubiprostone and forskolin-IBMX-cyclosporin A (FICA) in I sc experiments. In I sc experiments, cyclosporin A (a phosphatase 2B inhibitor), previously shown to increase ClC-2 Cl Ϫ currents (10) , was added to forskolin-IBMX to ensure measurement of a large sustained I sc . Patch-clamp experiments in T84 ClC-2 KD and CFTR KD cells confirmed the findings with recombinant hClC-2 and hCFTR, and the findings from these cell models were reflected in T84 cells. The results of the present studies demonstrate that it is possible to functionally differentiate between ClC-2 and CFTR Cl Ϫ channels. These results are also relevant to the determination of the target(s) of lubiprostone per se in stimulation of I sc in T84 cells and, by extension, to the basis for lubiprostone action in treatment of human intestinal dysfunction, such as irritable bowel syndrome and constipation-related disorders.
MATERIALS AND METHODS
Materials. Lubiprostone and DMSO were obtained from R-Tech Ueno (Tokyo, Japan); methadone hydrochloride, CFTRinh172, cyclosporin A, and MISSION short hairpin RNAs (shRNAs) targeting hClC-2 and hCFTR as glycerol stock and lentiviral particles from Sigma-Aldrich (St. Louis, MO); forskolin {7-deacetyl-7-[O-(N-methylpiperazino)-␥-butyryl]-dihydrochloride} from EMD Millipore-Calbiochem (Billerica, MA); and IBMX and 1-ethyl-2-benzimidazolinone (1-EBIO) from Tocris Cookson (Ellisville, MO). DASU-02 was a gift from Dr. Bruce Schultz (Department of Anatomy and Physiology, Kansas State University, Manhattan, KS). RIPA buffer was obtained from Cell Signaling Technology (Danvers MA); Pierce Halt protease inhibitor cocktail and Restore Western blot stripping buffer from Thermo Fisher Scientific (Rockford, IL); mouse monoclonal antibody to hClC-2 (catalog no. ab54664) and rabbit polyclonal antibody to GAPDH (catalog no. ab9485) from Abcam (Cambridge, MA); and mouse monoclonal antibody to hCFTR, clone M3A7 (catalog no. 05-583), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (catalog no. 12-349), and HRP-conjugated goat antirabbit IgG antibody (catalog no. 12-348) from EMD Millipore (Billerica, MA). IRDye 800CW-conjugated goat anti-mouse IgG (HϩL) highly cross-absorbed (catalog no. 926-32210), IRDye 680-conjugated goat anti-rabbit IgG (HϩL) highly cross-absorbed (catalog no. 926-32221), and Odyssey blocking buffer (catalog no. 927-40000) were obtained from LI-COR Biosciences (Lincoln, NE). Amersham ECL Western blotting detection reagent was obtained from GE Healthcare Biosciences (Pittsburgh, PA). The T84 cell line, 293EBNA cells (293 c18: CRL-10852), DMEM, and FBS were obtained from American Type Culture Collection (Manassas, VA). All other cell culture reagents, including MEM and Lipofectamine, were obtained from InVitrogen (Eugene, OR). Snapwell permeable supports were purchased from Corning (Corning, NY); ViroMag R/L from Ozbiosciences (Marseille, France); and borosilicate glass (catalog no. 7052) from Garner Glass (Claremont, CA). Methadone was dissolved in water; cyclosporin A in ethanol; and lubiprostone, forskolin-IBMX, 1-EBIO, CFTRinh172, and DASU-02 in DMSO. CFTRinh172 and DASU-02 were dissolved in DMSO and then diluted 1:1,000 in medium, with care taken to ensure that no precipitate was evident by examination of the medium microscopically. In a recent study of sweat glands (50) , limited aqueous solubility of CFTRinh172 was noted, with the limit being 5 M. The concentration of vehicle (DMSO and ethanol) was always kept at Յ0.2%.
Cell culture. HEK 293 cells transfected with hClC-2 and hCFTR were grown in MEM supplemented with 5% heat-inactivated horse serum, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin sulfate, and 300 g/ml G418, as previously described (8) . To test effectiveness of siRNAs in knocking down hClC-2, hClC-2/HEK293 cells were used. 293EBNA cells transfected with hClC-2 were grown in DMEM containing 10% FBS, 0.25 mg/ml G418, and 100 g/ml hygromycin, as previously described (7) . The 293EBNA cells were used to achieve higher expression of hClC-2 (7). Control (in the absence of activators) and stimulated (activated with lubiprostone or forskolin-IBMX) hClC-2 Cl Ϫ currents were fourfold greater in 293EBNA than HEK293 cells (7) . The T84 human cell line was grown in DMEM-Ham's F-12 medium with 6% heat-inactivated FBS, 15 mM HEPES, 14.3 mM NaHCO 3, 100 U/ml penicillin, and 100 g/ml streptomycin sulfate and then grown to confluence on 1.13-cm 2 Snapwell permeable supports (8) .
Knockdown of ClC-2 or CFTR in T84 cells. Five different short hairpin sequences (shRNAs) producing siRNAs targeting hClC-2 and hCFTR and a nontarget (NT) sequence in lentiviral vector pLKO.1, as well as control vector (mock), were tested. Lipofectamine was used to transfect hClC-2/HEK293 or hCFTR/HEK293 cells with shRNAs (as DNA). These cells were used to determine which siRNA was effective at knocking down hClC-2 or hCFTR function. T84 cells were then transduced with lentiviral particles containing the effective shRNA for hClC-2 (bp 1302-1322) or hCFTR (bp 4265-4286) knockdown using ViroMag R/L. Puromycin (5 g/ml) was used for selection.
Patch-clamp measurement of whole cell Cl Ϫ currents. Patch-clamp and analytic methods are described elsewhere (8) . Two voltage-clamp pulse protocols were used. For hClC-2/HEK293 and hCFTR/HEK293 cells, currents were elicited by voltage-clamp pulses between Ϫ140 and ϩ40 mV in 20-mV increments from a holding potential of Ϫ30 mV, and 200-ms recordings were made. For hClC-2/293EBNA, T84, T84 ClC-2 KD, and T84 CFTR KD cells, currents were elicited by voltage-clamp pulses between Ϫ160 and ϩ40 mV in 20-mV increments from a holding potential of Ϫ30 mV, and 1,500-ms recordings were made. For both protocols, current values were taken at 200 ms and normalized to capacitance. The bath (external) solution contained (in mM) 140 tetraethylammonium Cl, 1 MgCl2, 2 CaCl2, and 10 HEPES (pH 7.4). The pipette (internal) solution contained (in mM) 115 tetraethylammonium Cl, 2 MgCl2, 5 EGTA, and 10 HEPES (pH 7.4). Pipettes were prepared from borosilicate glass and pulled by a two-stage Narashige puller to produce 1-to 1.5-M⍀ resistance. Data acquired with an Axopatch CV-4 headstage, a Digidata 1200 digitizer, and an Axopatch 1D amplifier were analyzed using pClamp 6.04 (Axon Instruments, Union City, CA), Microsoft Excel, and Origin (OriginLab, Northampton, MA) software. Cell capacitances are indicated in the figure legends. Mean cell capacitances of hCFTR/ HEK293, hClC-2/293EBNA, T84 ClC-2 KD, and T84 CFTR KD cells were very similar: 17.1 Ϯ 2.0 pF (n ϭ 6), 15.0 Ϯ 0.8 pF (n ϭ 14), 14.4 Ϯ 1.3 pF (n ϭ 5), and 19.1 Ϯ 4.6 pF (n ϭ 6), respectively.
Isc measurements. The EasyMount Ussing chamber system (8 chambers) with VCCMC8 eight-channel current-voltage (I-V) clamps (Physiologic Instruments, San Diego, CA) was used for Isc measurements across confluent T84 cell monolayers, as previously described (8) . Transepithelial resistance of T84 cells was monitored with an EVOM epithelial voltohmmeter (World Precision Instruments). Cells were used when the transepithelial resistance of the monolayer was Ͼ1,200 ⍀. Solutions were continuously gassed with 95% O2-5% CO2 and stirred, and the temperature was held constant at 37°C with a heating block. The clamps were connected to Acquire and Analyze software (Physiologic Instruments) for automatic data collection from all eight of the Ussing chambers. Ag/AgCl reference electrodes were used to measure transepithelial voltage and passing current. The basolateral membrane bath solution contained (in mM) 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 K2HPO4, 1. Western blotting. Cell lysates were made of T84 ClC-2 KD, T84 CFTR KD, and appropriate mock-transduced T84 cells. Cells were washed with cold PBS and incubated with RIPA buffer containing freshly added 1 mM PMSF and 1 g/ml protease inhibitor cocktail for 5 min on ice. Cells were collected using cell scrapers, sonicated briefly, and centrifuged at 14,000 g at 4°C. The supernatant (cell lysate) was collected. Cell lysates (50 g) in 3ϫ SDS sample buffer (100% glycerol, 1 M Tris-Cl, pH 6.8, 20% SDS, 16% ␤-mercaptoethanol, and 0.006% bromophenol blue) were incubated for 5 min at 95°C for ClC-2 detection and for 30 min at 37°C for CFTR detection. The proteins were separated on 10% SDS-polyacrylamide gel for ClC-2 and on 7.5% SDS-polyacrylamide gel for CFTR and then transferred to a nitrocellulose membrane overnight at 4°C. For one experiment, membrane preparations were made from T84 mocktransduced and T84 ClC-2 KD cells. Cells were washed with cold PBS, removed using a cell scraper, and centrifuged at 100,000 g at 4°C for 36 min. The membrane pellet was resuspended in 10 mM Tris-Cl, pH 7.0, containing protease inhibitors (Halt protease inhibitor cocktail). Membrane protein (500 g) that had been heated for 5 min at 95°C was separated on 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane overnight at 4°C. Standard lanes were cut out and stained separately. Detection of ClC-2 was first carried out using fluorescently labeled secondary antibodies and then after stripping the membranes with Restore Western Blot Stripping Buffer for 15 min at room temperature, followed by washing 3 ϫ 5 min with PBS, using an ECL method that detects HRP-coupled secondary antibodies. CFTR was detected using the ECL method as indicated in the hCFTR monoclonal antibody specifications. For the fluorescence detection method, membranes were blocked for 2 h with Odyssey blocking buffer, probed with a 1:200 dilution of mouse monoclonal antibody to hClC-2 plus a 1:2,000 dilution of rabbit polyclonal antibody to GAPDH overnight at 4°C, washed five times for 5 min each with PBS-0.01% Tween 20, and then incubated for 1 h in darkness with IRDye 800CW-conjugated goat anti-mouse IgG (green fluorescence) for ClC-2 (95 kDa) and a 1:15,000 dilution of IRDye 680-conjugated goat anti-rabbit IgG (red fluorescence) for GAPDH (37 kDa). All antibodies were diluted in blocking buffer containing 0.01% Tween 20. Fluorescent protein bands were scanned and analyzed using a LI-COR Odyssey infrared imaging system. The protein band ratio of ClC-2 to GAPDH was calculated. For the ECL detection method, membranes were blocked for 1 h with 5% nonfat dry milk in PBS-0.05% Tween 20 (MLK-PBST), probed with 1:200 dilution of mouse monoclonal antibody to hClC-2 or 2 g/ml mouse monoclonal antibody against hCFTR overnight at 4°C, and then washed twice for 5 min each with water and three times for 5 min each with PBST. The membranes were then incubated for 1 h with a 1:2,000 dilution of HRP-conjugated goat anti-mouse IgG antibody, washed five times for 5 min each with PBST, and for CFTR detection only incubated in water for 30 min. All antibodies were diluted with 5% MLK-PBST. The protein band (170 kDa for CFTR or 95 kDa for ClC-2) was detected with ECL using Amersham ECL Western blotting detection reagent. The membranes were stripped with Restore Western blot stripping buffer for 15 min at room temperature and then washed three times for 5 min each with PBS. After they were blocked for 1 h with 5% MLK-PBST, the membranes were probed with a 1:2,000 dilution of rabbit polyclonal antibody to GAPDH overnight at 4°C, washed five times for 5 min each with PBST, and incubated for 1 h with a 1:2,000 dilution of HRP-conjugated goat anti-rabbit IgG antibody. After five 5-min washes with PBST, the GAPDH protein band (37 kDa) was also detected using ECL, as described above. The protein band ratios of ClC-2 to GAPDH and CFTR to GAPDH were calculated.
Statistical and regression analyses and reversal potentials. Statistical analyses were performed using SigmaPlot version 12 (Systat Software), with the critical significance level set at 0.05. Parametric tests were used in analysis of the data, which are expressed as means Ϯ SE (n ϭ number of independent observations). Concentration-dependent data were plotted on a semilogarithmic scale and fit by a four-parameter logistic function using nonlinear regression:
, where Imin and Imax represent minimum and maximum currents, x is inhibitor concentration, nH is Hill's slope, and IC50 is 50% effective inhibitor concentration. Results are expressed as the estimates of fit parameters Ϯ SE; r 2 is the regression coefficient, and P describes the significance of the fit. Group comparisons and comparisons of fit parameters (see equation above), Student's unpaired or paired t-test, or one-way repeatedmeasures ANOVA followed by all-pairwise multiple comparisons by the Holm-Sidak test were carried out.
Since there was a 27 meq/l Cl Ϫ gradient (146 mM Cl out Ϫ and 119 mM Cl in Ϫ ), CFTR data from Fig. 3B (ϩF/I) were fit to the Goldman-HodgkinKatz flux equation using SigmaPlot, and the best nonlinear least-squares fit was linear, with r 2 ϭ 0.992. Therefore, CFTR I-V curves were fit with a linear regression function. All I-V curves showed a small negative reversal potential of approximately Ϫ6 mV because of the 27 meq/l Cl Ϫ gradient. Reversal potentials were estimated using linear plots of all the CFTR data, and all r 2 values (given in figure legends) were highly significant with P Ͻ 0.0001. Reversal potentials for ClC-2, which exhibits inwardly rectified I-V curves, were estimated using a linear plot of Ϫ20-, 0-, and ϩ20-mV data.
RESULTS

Effect of CFTR inh 172 on Cl
Ϫ currents in recombinant hCFTR/HEK293 and recombinant hClC-2/293EBNA cells. To identify the target(s) of CFTR inh 172, its effect on recombinant hCFTR and hClC-2 Cl Ϫ currents was examined. Figure 1C shows summarized data at Ϫ140 mV. All multiple comparisons were highly significant (P Ͻ 0.001). Figure 1D shows that CFTR inh 172 inhibited forskolin-IBMX-stimulated CFTR Cl Ϫ currents in a concentration-dependent manner, with IC 50 at 133.6 Ϯ 23.4 nM (n ϭ 8). Maximal inhibition at 5 M CFTR inh 172 was 61.3%. The regression coefficient of the fit was 0.990, with high significance at P Ͻ 0.001. Others (25) reported data showing an estimated/approximate IC 50 of 300 nM using I sc .
Next, the effect of CFTR inh 172 on Cl Ϫ currents in recombinant hClC-2/293EBNA cells was investigated (Fig. 2) . Typical current recordings and the corresponding I-V curves are shown in Fig. 2A . Control currents were inwardly rectified, timeand voltage-dependent, and inhibited by 1 M CFTR inh 172. Figure 2B shows that 20 nM lubiprostone increased hClC-2 Cl Ϫ currents and subsequent addition of 1 M CFTR inh 172 inhibited the lubiprostone-stimulated Cl Ϫ current. These currents were also inwardly rectified, time-and voltage-dependent, and inhibited by 1 M CFTR inh 172. I-V curves showed a small negative reversal potential (approximately Ϫ6 mV), to be expected with a 27 meq/l Cl Ϫ gradient. Therefore, voltageactivated and lubiprostone-stimulated hClC-2 Cl Ϫ currents were inhibited by CFTR inh 172. Figure 2C shows that CFTR inh 172 caused a concentration-dependent decrease in lubiprostone-stimulated hClC-2 Cl Ϫ currents, with an IC 50 of 143.1 Ϯ 23.4 nM (n ϭ 8), which is not significantly different from that for hCFTR (see above). Maximum inhibition at 5 M CFTR inh 172 was 54.4%. The regression coefficient of the fit was 0.993, which was highly significant with P Ͻ 0.001. Control (without lubiprostone) hClC-2 Cl Ϫ currents were similarly inhibited by CFTR inh 172, with IC 50 ϭ 222 Ϯ 44 nM (n ϭ 8) and 63% maximum inhibition at 5 M CFTR inh 172. There was no meaningful difference between the IC 50 for control and lubiprostone-stimulated currents (P ϭ 0.14). CFTR inh 172 is, therefore, not CFTR-specific, but it is an equally potent inhibitor of both hClC-2 and hCFTR.
Fritsch et al. (20) reported that CFTR inh 172 (and GlyH-101) had multiple cellular effects, including depolarization of the mitochondrial membrane potential. Therefore, it was important to show that activation of ClC-2 by lubiprostone was not compromised by addition (and washout) of CFTR inh 172. As shown in the inset in Fig. 2C , multiple cycles of activation of hClC-2 by 100 nM lubiprostone followed by addition of CFTR inh 172 at increasing concentrations and washout did not affect the level of stimulation by lubiprostone. CFTR inh 172 inhibited lubiprostonestimulated hClC-2 Cl Ϫ currents in a concentration- dependent manner. This inhibition was reversible, since it was possible to wash out the inhibitor. Reversibility of CFTR inh 172 effects has been shown by others (25) . Therefore, the decreases in hClC-2 Cl Ϫ currents observed with CFTR inh 172 were not due to adverse or toxic effects on the cells. The effect of CFTR inh 172 on 5 M forskolin-20 M IBMX-stimulated hClC-2 Cl Ϫ currents was also examined. A summary of the results at Ϫ140 mV, together with those of voltage-activated (control) and lubiprostone-stimulated hClC-2 Cl Ϫ currents, are shown in Fig. 2D . CFTR inh 172 (1 M) significantly inhibited (P Ͻ 0.001) control hClC-2 Cl Ϫ currents. Lubiprostone significantly stimulated (P Ͻ 0.001) hClC-2 Cl Ϫ currents, which were significantly inhibited (P Ͻ 0.001) by 1 M CFTR inh 172. Forskolin-IBMX also significantly stimulated (P Ͻ 0.001) hClC-2 Cl Ϫ currents, which were also significantly inhibited (P Ͻ 0.001) by 1 M CFTR inh 172. These results (Figs. 1 and 2 ) further support the concept that Cl Ϫ current inhibition by CFTR inh 172 is not specific to hCFTR, since it also equipotently inhibited hClC-2 Cl Ϫ currents, whether control or lubiprostone-or forskolin-IBMX-stimulated.
Effect of DASU-02 on lubiprostone-stimulated hClC-2 and forskolin-IBMX-stimulated hCFTR Cl
Ϫ currents. DASU-02 was found to inhibit Cl Ϫ transport in pig colon, forskolinstimulated I sc in T84 cells, and recombinant CFTR Cl Ϫ channels expressed in L cells measured in excised membrane patches (31) . DASU-02 had no effect on recombinant rabbit ClC-2 expressed in oocytes (Bruce Schultz, unpublished observations). Figure 3 shows that Cl Ϫ currents of hCFTR/ HEK293 cells were significantly stimulated (P Ͻ 0.005) by forskolin-IBMX and significantly inhibited (P Ͻ 0.02) by 100 M DASU-02, the positive control experiment. Corresponding I-V curves (Fig. 3B) were linear, with a reversal potential of Ϫ11.7 Ϯ 1.8 mV (n ϭ 3). As shown in Fig. 4 , Cl Ϫ currents of recombinant hClC-2/293EBNA cells were significantly stimulated (P Ͻ 0.001) by 20 nM lubiprostone, and 100 M DASU-02 had no effect. Recently, it was shown that methadone inhibited hClC-2, but not hCFTR, Cl Ϫ currents (7), thus distinguishing between these channels. Therefore, 1 M methadone was tested after DASU-02, and it significantly inhibited (P Ͻ 0.001) the lubiprostone-stimulated current. CFTR inh 172 (1 M) further inhibited this current (P Ͻ 0.001), as expected The effect of increasing DASU-02 concentrations (up to 300 M) on recombinant hCFTR and hClC-2 Cl Ϫ currents was then investigated. DASU-02 was previously shown to be maximally effective at 300 M (600 M gave no further effect), with an IC 50 of ϳ100 M (31). Figure 4D shows that DASU-02 inhibited recombinant hCFTR Cl Ϫ currents in a concentration-dependent manner, with an IC 50 of 86.5 Ϯ 10.6 M (n ϭ 5), similar to that previously reported (29) , and with maximum inhibition by 300 M DASU-02 of 68.6%. The regression coefficient of the fit for hCFTR inhibition was 0.999, which was significant with P Ͻ 0.02. In contrast, DASU-02 had no effect on recombinant hClC-2 Cl Ϫ currents. Data for hClC-2 could not be fit by a four-parameter logistic function (P Ͼ 0.80). From these results with DASU-02 and those with methadone (present data and Ref. 7) , it should be possible to use these agents to distinguish between CFTR and ClC-2 Cl Ϫ channel currents in any epithelia or tissues, including T84 cells, whereas CFTR inh 172 cannot be used, since it equipotently inhibits both ClC-2 and CFTR Cl Ϫ currents. Effect of lubiprostone and FICA on I sc in the human T84 cell line: effect of basolateral nystatin and 1-EBIO. In all I sc experiments 100 nM lubiprostone and 5 M forskolin-20 M IBMX-20 M cyclosporin A (FICA) were used. The effect of sequential additions of lubiprostone followed by FICA or FICA followed by lubiprostone with and without 200 g/ml nystatin on I sc in T84 cells was determined with a 12-fold basolateral-to-apical Cl Ϫ gradient. Under these conditions, I sc is only due to Cl Ϫ movement through apical membrane Cl Ϫ channels (1), since basolateral membrane effects are removed by nystatin, and then the apical membrane conductance alone is rate-limiting. Cyclosporin A (a phosphatase 2B inhibitor) was added to forskolin-IBMX in I sc experiments in T84 cells to ensure measurement of a large sustained I sc (Fig. 5A) (12, 13) . It is perhaps of interest to point out that the maximum I sc measured with nystatin and 1-EBIO were similar. To further characterize these two I sc components, the effects of inhibitors were examined. Figures 1-4 show that CFTR inh 172 equipotently inhibited recombinant hClC-2 and hCFTR, while DASU-02 differentially inhibited hCFTR, but not hClC-2. Therefore, the effect of CFTR inh 172 on lubiprostone-and FICA-stimulated I sc in nystatin-permeabilized T84 cells was examined. CFTR inh 172 (10 M) was added before treatment with lubiprostone ϩ FICA (Fig. 6A) or with lubiprostone followed by FICA or FICA followed by lubiprostone (Fig. 6B) . In all cases, 10 M CFTR inh 172 inhibited a major portion (Ͼ80%) of the lubiprostone-and FICA-stimulated I sc . This was expected, since CFTR inh 172 inhibited both recombinant hClC-2 and hCFTR ( Figs. 1 and 2 ). The effect of DASU-02 on FICA-stimulated and lubiprostone-stimulated I sc in T84 cells is shown in Fig. 6, C findings with recombinant hClC-2 and hCFTR and indicate that DASU-02 differentially inhibits CFTR, but not ClC-2, in T84 cells. Lubiprostone-stimulated I sc with DASU-02 was significantly different from that without DASU-02 at two data points (P Ͻ 0.0005 and P Ͻ 0.005), and this cannot be explained.
Effect of CFTR inh 172 and DASU-02 on lubiprostone-and FICA-stimulated I sc in T84 cells.
Knockdown of ClC-2 or CFTR in T84 cells. To further distinguish between ClC-2 and CFTR in T84 cells, ClC-2 or CFTR channels were knocked down using stable transduction with appropriate shRNAs. Functional studies on these T84 cells were then carried out. To identify effective siRNAs targeting hClC-2 and hCFTR, the siRNAs were expressed in hClC-2/HEK293 or hCFTR/HEK293 cells, which were then tested for Cl Ϫ current responses to lubiprostone or forskolin-IBMX, respectively. Mock-and NT-transfected cells were also tested. Figure 7 , A and B, identifies siRNAs that abolished the hClC-2 response to 20 nM lubiprostone and the hCFTR response to 5 M forskolin-20 M IBMX. These siRNAs were then used to knock down ClC-2 and CFTR, respectively, in T84 cells. Western blots were performed on mock-and shRNA-transduced T84 cells (Fig. 7, C and D) . GAPDH was used to normalize the results. In these Western blots, knockdown of ClC-2 and CFTR in T84 cells resulted in 82.8% and 94.5% knockdown of ClC-2/GAPDH and CFTR/GAPDH, respectively. In six gels of T84 ClC-2 KD cells, five were cell lysates and one was a membrane preparation, and similar results were obtained. The mean percent knockdown of ClC-2/GAPDH in T84 cells was 79.1 Ϯ 4.0% (n ϭ 6). Effects of activators and inhibitors on Cl Ϫ channel currents in T84 ClC-2 KD and T84 CFTR KD cells were then examined.
Cl Ϫ currents in T84 ClC-2 KD (CFTR present) and T84 CFTR KD (ClC-2 present) cells: effects of activators and inhibitors.
Experiments carried out on T84 ClC-2 KD cells wherein ClC-2 was knocked down, but CFTR was present, are shown in Fig. 8 
CFTR inh 172 on Cl
Ϫ currents measured by whole cell patch clamp. In T84 ClC-2 KD cells, there was no response to lubiprostone but a large and significant response (P Ͻ 0.001) to forskolin-IBMX. Methadone had no effect, but DASU-02 significantly inhibited (P Ͻ 0.001) the forskolin-IBMX-stimulated Cl Ϫ current, and CFTR inh 172 further inhibited (P Ͻ 0.001) the current. These findings indicate that ClC-2 was responsible for lubiprostone stimulation, since ClC-2 and the lubiprostone response were both absent in these cells. The forskolin-IBMX stimulation and lack of inhibition by methadone, but inhibition by DASU-02 and CFTR inh 172, reflected CFTR-mediated Cl Ϫ currents in these T84 ClC-2 KD cells. In addition, currents were not time-or voltagedependent. Rather, I-V curves (Fig. 8B) were linear, with a reversal potential of Ϫ6.8 Ϯ 0.8 mV (n ϭ 6).
Similar experiments were carried out on T84 CFTR KD cells wherein CFTR is absent, but ClC-2 is present. In Fig. 9 , 20 nM lubiprostone stimulated the Cl Ϫ current significantly (P Ͻ 0.001), and 1 M methadone significantly inhibited (P Ͻ 0.001) and 300 M CdCl 2 , a ClC-2 inhibitor (7), further inhibited (P Ͻ 0.001) this current. As shown in Fig. 10 , 5 M forskolin-20 M IBMX also significantly stimulated (P Ͻ 0.001) the Cl Ϫ current and 100 M DASU-02 had no effect, but 1 M methadone significantly inhibited (P Ͻ 0.001) and 1 M CFTR inh 172 further inhibited (P Ͻ 0.05) this current. In both experiments, the Cl Ϫ currents were time-and voltagedependent, and I-V curves were inwardly rectified, with reversal potentials of Ϫ6.0 Ϯ 0.6 mV (n ϭ 4) and Ϫ8 Ϯ 1 mV (n ϭ 5) in Figs. 9B and 10B , respectively. Results shown in Figs. 9 and 10 would be expected if only ClC-2 was present. T84 ClC-2 KD and T84 CFTR KD cells, when cultured on permeable supports, did not form tight enough junctions to allow us to carry out I sc experiments. This is perhaps not surprising, since it has been established that ClC-2 is essential for the tight junction formation (27) (28) (29) (30) . A recent study suggests that CFTR may also be involved in tight junction formation (22) .
DISCUSSION
Both ClC-2 and CFTR Cl Ϫ channels are often both present in many epithelia, including T84 cells, and nonepithelial tissues (3, 5, 8, 14, 18, 23, 34 -36, 46, 48) . Cl Ϫ transport in these cells/tissues is activated by lubiprostone or forskolin or both (2-4, 7, 8, 12, 14, 27, 35, 36, 48) . The problem is how to distinguish between these two Cl Ϫ channels when they are present together in the same cells and in the same apical membrane (8, 23) . The present studies were designed to investigate whether pharmacological agents could be used to functionally distinguish/differentiate between ClC-2 and CFTR. Of particular interest was CFTR inh 172, originally described as a CFTR inhibitor that does not inhibit Ca 2ϩ -activated Cl Ϫ channels, volume-activated Cl Ϫ channels, ATP-activated K ϩ channels, or several transporters (25) . Inhibition of Cl Ϫ transport by CFTR inh 172 has been widely used to conclude that Cl Ϫ currents in tissues such as T84 cells (2, 4, 45) , lung epithelia (33), intestine (2, 4) , and smooth muscle (36, 48) were occurring through CFTR, and not ClC-2 or some other Cl Ϫ , channel. DASU-02, another CFTR inhibitor (31) that has not been widely characterized or used, was also examined. To our knowledge, the effects of CFTR inh 172 and DASU-02 on ClC-2 have not been tested until the present studies. In contrast, methadone has recently been shown to inhibit ClC-2, but not CFTR (7). Thus methadone inhibited lubiprostone-stimulated I sc in T84 cells and lubiprostone-and forskolin-IBMX-stimulated Cl Ϫ currents in recombinant hClC-2/293EBNA cells. However, methadone had no effect on forskolin-IBMX-stimulated Cl Ϫ currents in recombinant hCFTR/HEK293 cells. Recently, the peptide toxin inhibitor GaTx2 has become available (47). It does not inhibit CFTR, but it potently inhibits ClC-2 (IC 50 ϳ20 nM). It would be of great interest to investigate the effects of GaTx2 on lubiprostone-stimulated I sc in T84 cells. GaTx2 has been shown to inhibit lubiprostoneactivated, ClC-2-mediated nasal potential difference in mice (37) at high concentrations (100 nM) but, to our knowledge, has not been tested on I sc in T84 cells.
Lubiprostone potently activates ClC-2 from all species tested: human, rabbit, mouse, and rat. However, there are differences in potency (7-9): EC 50 values of 27.6 Ϯ 4.5 nM (n ϭ 4) for or without nystatin and with a basolateral-to-apical Cl Ϫ gradient. Nystatin was added at 1 min. Effects of lubiprostone and FICA were measured. ϩnyst: OE, lubi (1st arrow) followed by FICA (2nd arrow) (n ϭ 8); , FICA (1st arrow) followed by lubi (2nd arrow) (n ϭ 9); Ϫnyst: o, lubi (1st arrow) followed by FICA (2nd arrow) (n ϭ 3); OE, FICA (1st arrow) followed by lubi (2nd arrow) (n ϭ 4). *P Ͻ 0.005 vs. Ϫnyst. B: Isc was measured in T84 cells with 300 M 1-EBIO added apically and a basolateral-to-apical Cl Ϫ gradient. 1-EBIO was added at 1 min. Effects of lubiprostone and FICA were measured. OE, lubi (1st arrow) followed by FICA (2nd arrow) (n ϭ 3); , FICA (1st arrow) followed by lubi (2nd arrow) (n ϭ 3). Values are means Ϯ SE.
human, 350.0 Ϯ 37.6 nM (n ϭ 3) for rabbit, and 64.3 Ϯ 3.7 nM (n ϭ 4) for mouse likely a reflection of different sequence at the binding site on ClC-2 (9). Although lubiprostone potently activates recombinant hClC-2 Cl Ϫ channel currents and Cl Ϫ transport (I sc ) in T84 cells, it does not activate recombinant hCFTR Cl Ϫ channel currents (8) . These data suggest that lubiprostone's effects are through ClC-2, and not CFTR (7, 8) . Lubiprostone also stimulated ClC-2 Cl Ϫ channel currents in A6 cells at the single-channel level at low concentrations (EC 50 ϭ 69 nM), but, in addition, A6 cell CFTR Cl Ϫ channels were reported to be stimulated by ϳ10-fold higher lubiprostone concentrations (EC 50 ϳ791 nM) (3) . Two recent studies showed that lubiprostone stimulation of Cl Ϫ secretion in T84 cells was inhibited by CFTR inh 172 (2, 4), suggesting that lubiprostone activates CFTR, not ClC-2. However, before such a conclusion can be drawn, the effect of CFTR inh 172 on ClC-2 would need to be examined, since T84 cells contain both CFTR and ClC-2 (8, 23), as presented here.
It is well established that forskolin activates CFTR (16, 38) . When cellular processes (e.g., Cl Ϫ secretion) are activated by forskolin, the common interpretation is that only CFTR is involved. This has been further supported by CFTR inh 172 inhibition of such forskolin-activated processes, because many authors have assumed that CFTR inh 172 is "CFTR-specific" (2, 4, 25, 33, 45) . On the other hand, it is less widely recognized that forskolin also activates recombinant hClC-2, inhibitable by the PKA inhibitor myristoylated PKI (mPKI) (7, 8, 10, 44) . Indeed, the unique PKA phosphorylation sites (RRAT and RGET) responsible for PKA activation of hClC-2 have been identified by site-directed mutagenesis (10) . These phosphorylation sites are absent from the rat and mouse (9, 10, 19, 46) . Therefore, it is not surprising that although rat ClC-2 can be phosphorylated by PKA, this did not result in Cl Ϫ current activation (32) .
In all studies, great care is essential when "specific/selective" pharmacological agents (inhibitors or activators), which in many cases have not been thoroughly characterized, are used. They all have the potential to exhibit numerous additional effects: case-in-point, the inhibitor CFTR inh 172 and the activator forskolin. Therefore, in the present studies, experiments were performed on several different models: heterologously expressed recombinant hClC-2 and hCFTR Cl Ϫ channels, T84 cells that contain both channels, and, finally, T84 cells in which ClC-2 or CFTR channels were knocked down using siRNA techniques. In whole cell patch-clamp experiments, CFTR inh 172 inhibited recombinant lubiprostone-stimulated hClC-2 and forskolin-IBMX-stimulated hCFTR Cl Ϫ currents equipotently with half-maximal inhibition at 143.1 Ϯ 23.4 nM (n ϭ 8) and 133.6 Ϯ 23.4 nM (n ϭ 8), respectively. CFTR inh 172 inhibited control hClC-2 Cl Ϫ currents, hClC-2 Cl Ϫ currents stimulated by lubiprostone or forskolin-IBMX, and I sc in T84 cells stimulated by lubiprostone, forskolin (FICA), or a combination of the two. CFTR inh 172 thus inhibits both CFTR and ClC-2 and cannot be used to distinguish between ClC-2 and CFTR involvement in any cellular process, e.g., stimulation of I sc in T84 cells that contain both channels. In contrast, in the present studies DASU-02 differentially inhibited recombinant hCFTR, but not hClC-2, Cl Ϫ currents, and it partially inhibited forskolin-stimulated, but not lubiprostone-stimulated, I sc in T84 cells. As previously shown (7), methadone differentially inhibited hClC-2, and not hCFTR. Therefore, DASU-02 and methadone, but not CFTR inh 172, can be used to differentiate between ClC-2 and CFTR. In addition, GaTx2, shown to differentially inhibit ClC-2, and not CFTR, Cl Ϫ currents (47) and a basolateral-to-apical Cl Ϫ gradient. Nystatin was added at 1 min, both inhibitors were added at 2 min, and lubiprostone and FICA were used. A: effects of lubiprostone and FICA added together at the arrow were measured in the presence and absence of 10 M CFTRinh172. }, ϪCFTRinh (n ϭ 3); {, ϩCFTRinh (n ϭ 3). *P Ͻ 0.025 vs. ϪCFTRinh. B: effects of lubiprostone and FICA added sequentially were measured in the presence and absence of 10 M CFTRinh172. ϪCFTRinh (n ϭ 3): OE, lubi (1st arrow) followed by FICA (2nd arrow) (n ϭ 4);
, FICA (1st arrow) followed by lubi (2nd arrow) (n ϭ 3); ϩCFTRinh: ᮀ, lubi (1st arrow) followed by FICA (2nd arrow) (n ϭ 5); , FICA (1st arrow) followed by lubi (2nd arrow) (n ϭ 3). *P Ͻ 0.0005 vs. ϪCFTRinh. #P Ͻ 0.005 vs. ϪCFTRinh. C: effect of FICA was measured in the presence and absence of 300 M DASU-02. , Ϫdasu (n ϭ 13); OE, ϩdasu (n ϭ 3). *P Ͻ 0.001 vs. Ϫdasu. D: effect of lubiprostone was measured in the presence and absence of 300 M DASU-02. , Ϫdasu (n ϭ 17); ᮀ, ϩdasu (n ϭ 4). *P Ͻ 0.0005 vs. Ϫdasu. #P Ͻ 0.005 vs. Ϫdasu. NS, not significantly different. Values are means Ϯ SE. also prove to be very useful in resolving these two channels in complex epithelia such as T84 cells. It must be noted that whichever inhibitor (CFTR inh 172, methadone, DASU-02, or GaTx2) is used, there is only partial inhibition (50 -70%) of ClC-2 or CFTR Cl Ϫ currents in all cells or tissues (2, 4, 7, 31, 37, 47, 50) . Cl Ϫ transport across intact polarized epithelial cells is complex and involves Cl Ϫ movement across the basolateral membrane followed by Cl Ϫ exit across the apical membrane through Cl Ϫ conductances. To measure I sc due solely to apical Cl Ϫ transport, the basolateral membrane was permeabilized with nystatin and a basolateral-to-apical gradient was applied (1) . In the present studies consecutive additions of lubiprostone followed by FICA (or FICA followed by lubiprostone) to T84 cells treated basolaterally with nystatin resulted in two consecutive increases in I sc , i.e., two components of I sc . Without nystatin, a small increase in I sc was observed with lubiprostone or FICA, and subsequent addition of FICA or lubiprostone, respectively, had no further effect. Thus only a single component of I sc was evident in the absence of basolateral nystatin, as observed by Ao et al. (2) . Two components of I sc were also observed when 1-EBIO was used to activate basolateral Ca 2ϩ -activated K ϩ channels. Ao et al. (2) and Bijvelds et al. (4) failed, for the most part, to incorporate the use of nystatin or 1-EBIO in their experiments examining the effects of lubiprostone and forskolin in T84 cells. In addition and importantly, these authors did not take into account that human (but not rat or mouse) ClC-2 is also activated by forskolin-IBMX through a PKA pathway (7) (8) (9) (10) 44) . This introduces a confounding variable: it would be expected that part of a forskolin response in I sc studies of T84 cells is likely due to activation of ClC-2 in addition to activation of CFTR. In these two reports (2, 4) , CFTR inh 172 inhibited lubiprostone-and forskolin-stimulated I sc in T84 cells, leading to the conclusion that lubiprostone acts through stimulation of CFTR, and not ClC-2. However, CFTR inh 172 was not tested on recombinant hClC-2 until the present studies. (20) . CFTR inh 172 also exerted some inhibitory effects on Na ϩ transport (50) . In addition, it has been reported that not all CFTR molecules from various species are inhibited equally by CFTR inh 172 and GlyH-101, despite the fact that they have a similar sequence in the proposed binding site on CFTR (40) .
Ao et al. (2) 5) . GAPDH was the loading control. Ratio of ClC-2 to GAPDH decreased by 82.8%. Percent KD of ratio of ClC-2 to GAPDH from 6 gels was 79.1 Ϯ 4.0% (n ϭ 6). *P Ͻ 0.001 vs. mock. D: ECL-stained Western blot and quantitation of T84 CFTR KD cells (lanes 5-7) compared with mock-transduced T84 cells (lanes 1-3) . GAPDH was the loading control. Lane 4, standards. In T84 CFTR KD cells, ratio of CFTR to GAPDH was decreased by 94.5%. *P Ͻ 0.001 vs. mock. Values are means Ϯ SE.
itor, to conclude that lubiprostone acted via PKA activation. This is in direct contrast to previously reported data using mPKI (7, 8, 10, 44) , which acts by binding to the free catalytic subunit of PKA with high affinity (K i ϭ 36 nM), thereby inhibiting PKA phosphorylation (11, 17) . Lubiprostone activation of recombinant hClC-2 Cl Ϫ currents is not inhibited by mPKI, and in these studies parallel experiments on forskolin-IBMX-stimulated hClC-2 Cl Ϫ currents were always performed to ensure that mPKI was active and effective (7, 8, 10, 44) . H89, a PKA inhibitor, is well known to have many additional effects, some referred to as nonspecific, off target, or other effects (21, 24, 26, (41) (42) (43) . This was sorted out in complex systems by testing H85, an inactive form of H89, together with the active form (21, 26, (41) (42) (43) . If effects were only evident with H89, and not with H85, they were considered specific. If both forms exhibited similar effects, they were considered nonspecific or other effects. Unfortunately, the inactive form, H85, is unavailable. In the category of other effects, several studies concluded that H89 had direct effects on several different ion channels (21, 26, 41, 42) . Inactive forms of pharmacological agents are not often available; therefore, it is important to test the compounds on potential targets separately, especially if it is desired to exclude one or more targets as responsible for the compound's effects. H89 was compared with other PKA inhibitors, including mPKI, in some studies, and mPKI is considered to be more specific than H89 (24).
Only with the identification and characterization of the differential inhibitors of ClC-2 and CFTR, methadone and DASU-02, and the availability of T84 ClC-2 KD and CFTR KD cells, together with studies of the effects of treatments on recombinant hClC-2 and hCFTR in whole cell patch clamp, has it been possible to investigate whether ClC-2 is the target of lubiprostone in T84 cells and whether both ClC-2 and CFTR could play a role in Cl Ϫ secretion by T84 cells. After experiments on the target channels in simplified recombinant systems, experiments were carried out using T84 cells that contain both possible channel targets. As a final step, to further separate and characterize T84 cell Cl Ϫ currents, T84 ClC-2 KD and CFTR KD cells were developed and used in the present studies and led to very clear results. When ClC-2 was knocked down, there was no lubiprostone response, but there was still a forskolin-IBMX response that was sensitive to DASU-02 but insensitive to methadone, reflecting CFTR function. When CFTR was knocked down, there was a lubiprostone response and a forskolin-IBMX response, which were insensitive to DASU-02 and inhibited by methadone, reflecting ClC-2 function. These findings indicate that ClC-2 and CFTR are present in T84 cells, that low concentrations of lubiprostone activate ClC-2, and not CFTR, and that both channels are activated by forskolin-IBMX. Methadone and DASU-02 can be successfully used to distinguish between ClC-2-and CFTR-mediated Cl Ϫ currents/transport in epithelial cells. Overall, the results of the present study support the view that two pharmacological agents, methadone and DASU-02, can be used to differentiate between ClC-2 and CFTR. Methadone, but not DASU-02, inhibits ClC-2, and DASU-02, but not methadone, inhibits CFTR. CFTR inh 172 is not CFTR-specific, but it equipotently inhibits both ClC-2 and CFTR and, therefore, cannot be used to distinguish between ClC-2 and CFTR. Lubiprostone's target is ClC-2, not CFTR, and both channels are activated by forskolin-IBMX but have different inhibitor sensitivities. Both ClC-2 and CFTR are present and likely play roles in Cl Ϫ secretion by T84 cells. 
